Fluconazole sensitivities of Candida species isolated from the mouths of terminally ill cancer patients

American Journal of Hospice and Palliative Medicine

Volumn 15, Issue 6, 1998, Pages 315-319

  Ball, Karen ^a   Sweeney, M Petrina ^a   Baxter, Wendy P ^b   Bagg, Jeremy ^a  

^a GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^b ACCORD Hospice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CLASSIFICATION; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; NEOPLASM; RISK FACTOR; TERMINAL CARE; THRUSH;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, ORAL; FEMALE; FLUCONAZOLE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; RISK FACTORS; TERMINAL CARE;

EID: 0032199394     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990919801500605     Document Type: Article

References (22)

1. Jobbins J, Bagg J, Finlay IG, et al: Oral and dental disease in terminally ill cancer patients. Brit Med J. 1992;304:1612.
2. Sweeney MP, Bagg J, Baxter WP, et al: Oral disease in terminally ill cancer patients with xerostomia. Oral Oncology. 1998;34:123-126.
3. Finlay IG: Oral symptoms and candida in the terminally ill. Brit Med J. 1986;292:592-593.
4. Xu T, Levitz SM, Diamond R, et al: Anticandidal activity of major human salivary histatins. Infect Immun. 1991;59:2549-2554.
5. Karyotakis NC, Anaissie EJ: The new antifungal azoles: fluconazole and itraconazole. Curr Opinion Infect Dis. 1994;7:658-666.
6. Hay RJ: Antifungal therapy and the new azole compounds. J Antimicrob Chemother. 1991;28(Suppl. A): 35-46.
7. Sugar AM: Fluconazole and itraconazole: Current status and prospects for antifungal therapy. In: Remington JS, Swartz MN (eds.): Current Clinical Topics in Infectious Diseases. Volume 13. Oxford, Blackwell Scientific Publications Limited, 1993; 74-98.
8. Warnock DW: Azole drug resistance in Candida species. J Med Microbiol. 1992;37:225-226.
9. Sangeorzan JA, Bradley S, He X, et al: Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994;97:339-346.
10. Warnock DW, Burke J, Cope NJ, et al: Fluconazole resistance in Candida glabrata. Lancet. 1988;2:1310.
11. Wingard JR, Merz WG, Rinaldi MG, et al: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-1277.
12. Jobbins J, Bagg J, Parsons K, et al: Oral carriage of yeasts, coliforms and staphylococci in patients with advanced malignant disease. J Oral Pathol Med. 1992;21:305-308.
13. Arendorf TM, Walker DM: The prevalence and intra-oral distribution of Candida albicansin man. Archs Oral Biol. 1980;25:1-10.
14. Samaranayake LP, MacFarlane TW, Williamson MI: Comparison of Sabouraud dextrose and Pagano-Levin agar for detection and isolation of yeasts from oral samples. J Clin Microbiol. 1987;25:162-164.
15. Warren NG, Shadomy HJ: Chapter 60. Yeasts of medical importance. In Balows A, Hausler WJ, Herrmann KL, et al (eds.): Manual of Clinical Microbiology. Fifth edition. Washington DC, American Society for Microbiology, 1991; 617-629.
16. Dupont B, Drouhet E: Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody positive group of patients. J Med Vet Mycol. 1988;26:67-71.
17. Pfaller MA, Rex JH, Rinaldi MG: Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis. 1997;24:776-784.
18. Dannaoui E, Colin S, Pichot J, et al: Evaluation of the E-test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis. Eur J Clin Microbiol Infect Dis. 1997;16:228-232.
19. Rex JH, Pfaller MA, Galgiani JN, et al: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivocorrelation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997;24:235-247.
20. Odds FC: Itraconazole-a new oral antifungal agent with a very broad spectrum of activity in superficial and systemic mycoses. J Dermatol Sci. 1993;5:65-72.
21. Cartledge JD, Midgley J, Gazzard BG: Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS. 1997;11:1839-1844.
22. Marco F, Pfaller MA, Messer S, et al: In vitro activities of voriconazole (UK-109, 496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother. 1998;42:161-163.